Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
329.60
16.80(3.98%)
At close: 4:00 PM EDT
329.60
16.80(3.98%)
Day’s Range― - ―
52-Week Range209.20 - 527.00
Previous CloseN/A
Volume19.47K
Average Volume (3M)13.56K
Market Cap
₪27.26M
Enterprise Value25.31
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume5,007
30 Day Avg. Volume13,559
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage limits refinancing and solvency risk, giving the company a less burdened capital structure than a highly indebted business. This provides some financial resilience and preserves flexibility to address operating challenges over the next several quarters.
Limited Debt Service BurdenA minimal debt burden reduces the amount of cash that must be directed toward interest and principal obligations. That does not solve the company’s operating weakness, but it lowers fixed financial pressure and may help preserve resources while the business remains pre-commercial.
Existing Equity CushionThe company still had a meaningful equity base at the latest reported period, providing some capitalization to support ongoing operations despite losses. The cushion has declined materially, so this is a limited strength rather than evidence of balance-sheet improvement.
Bears Say
Minimal And Volatile RevenueRevenue has not established a dependable commercial base and reached zero in the latest reported year. Without recurring sales growth, the company lacks evidence that its model can scale, absorb its cost structure, or develop durable operating leverage over the next several quarters.
Persistent Operating LossesRecurring operating and net losses indicate that the current business model is not yet economically self-sustaining. Continued losses can erode capital, restrict strategic flexibility, and require management to depend on future funding or a significant improvement in commercial performance.
Ongoing Cash BurnPersistent negative operating and free cash flow shows that reported losses are translating into actual cash outflows rather than being mainly accounting effects. Continued burn increases dependence on external funding and makes the company vulnerable if revenue generation does not improve.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 527.00 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪27.26M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 205 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Aug 24, 2026. The company reported -35.6 earnings per share for the quarter.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -35.6 in its last earnings report. Following the earnings report the stock price went up 1.185%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.